Literature DB >> 16267768

Parasitological rebound effect and emergence of pyrimethamine resistance in Plasmodium falciparum after single-dose sulfadoxine-pyrimethamine.

Florian Marks1, Vera von Kalckreuth, Robin Kobbe, Samuel Adjei, Ohene Adjei, Rolf D Horstmann, Christian G Meyer, Jurgen May.   

Abstract

Intermittent preventive treatment for malaria in infants (IPTi) is a promising malaria control strategy. However, mass preventive treatment for malaria inherently bears the risk of increasing drug resistance. Here, the effect of single-dose sulfadoxine-pyrimethamine (S-P) versus placebo on Plasmodium falciparum infection rates was assessed in 63 selected infants who were aparasitemic at enrollment. An increase in the proportion of infants with isolates exhibiting drug resistance-associated mutations was detected 3 weeks after drug application in the treatment group. S-P, in the setting of IPTi, appears to cause a parasitological rebound effect in which there is selection of drug-resistant parasites for a short period after drug clearance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16267768     DOI: 10.1086/497698

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  High prevalence of dihydrofolate reductase gene mutations in Plasmodium falciparum parasites among pregnant women in Nigeria after reported use of sulfadoxine-pyrimethamine.

Authors:  Olusola Ojurongbe; Christian N Nguetse; Samuel A Fayemiwo; Catherine O Falade; Taiwo A Ojurongbe; Bolaji N Thomas; Christian G Meyer; Thirumalaisamy P Velavan
Journal:  Pathog Glob Health       Date:  2018-01-10       Impact factor: 2.894

2.  Discovery of a Plasmodium falciparum glucose-6-phosphate dehydrogenase 6-phosphogluconolactonase inhibitor (R,Z)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-(2-fluorobenzylidene)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazine-6-carboxamide (ML276) that reduces parasite growth in vitro.

Authors:  Janina Preuss; Patrick Maloney; Satyamaheshwar Peddibhotla; Michael P Hedrick; Paul Hershberger; Palak Gosalia; Monika Milewski; Yujie Linda Li; Eliot Sugarman; Becky Hood; Eigo Suyama; Kevin Nguyen; Stefan Vasile; Eduard Sergienko; Arianna Mangravita-Novo; Michael Vicchiarelli; Danielle McAnally; Layton H Smith; Gregory P Roth; Jena Diwan; Thomas D Y Chung; Esther Jortzik; Stefan Rahlfs; Katja Becker; Anthony B Pinkerton; Lars Bode
Journal:  J Med Chem       Date:  2012-08-06       Impact factor: 7.446

3.  Plasmodium falciparum and Plasmodium vivax genotypes and efficacy of intermittent preventive treatment in Papua New Guinea.

Authors:  Celine Barnadas; Nicolas Senn; Jonah Iga; Lincoln Timinao; Sarah Javati; Elisheba Malau; Patricia Rarau; John C Reeder; Peter Siba; Harin Karunajeewa; Peter A Zimmerman; Timothy M Davis; Ivo Mueller
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  The aminopeptidase inhibitor CHR-2863 is an orally bioavailable inhibitor of murine malaria.

Authors:  Tina S Skinner-Adams; Christopher L Peatey; Karen Anderson; Katharine R Trenholme; David Krige; Christopher L Brown; Colin Stack; Desire M M Nsangou; Rency T Mathews; Karine Thivierge; John P Dalton; Donald L Gardiner
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

5.  Drug coverage in treatment of malaria and the consequences for resistance evolution--evidence from the use of sulphadoxine/pyrimethamine.

Authors:  Allen L Malisa; Richard J Pearce; Salim Abdulla; Hassan Mshinda; Patrick S Kachur; Peter Bloland; Cally Roper
Journal:  Malar J       Date:  2010-07-05       Impact factor: 2.979

6.  Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.

Authors:  W E Harrington; T K Mutabingwa; A Muehlenbachs; B Sorensen; M C Bolla; M Fried; P E Duffy
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

7.  Intermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.

Authors:  Frank P Mockenhaupt; Klaus Reither; Philipp Zanger; Felix Roepcke; Ina Danquah; Eiman Saad; Peter Ziniel; Stephen Y Dzisi; Marc Frempong; Patrick Agana-Nsiire; Felicia Amoo-Sakyi; Rowland Otchwemah; Jakob P Cramer; Sylvester D Anemana; Ekkehart Dietz; Ulrich Bienzle
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

Review 8.  Monitoring antifolate resistance in intermittent preventive therapy for malaria.

Authors:  Meera Venkatesan; Michael Alifrangis; Cally Roper; Christopher V Plowe
Journal:  Trends Parasitol       Date:  2013-08-12

9.  Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.

Authors:  Mayke J A M Oesterholt; Michael Alifrangis; Colin J Sutherland; Sabah A Omar; Patrick Sawa; Christina Howitt; Louis C Gouagna; Robert W Sauerwein; Teun Bousema
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

10.  Molecular markers of resistance to sulphadoxine-pyrimethamine one year after implementation of intermittent preventive treatment of malaria in infants in Mali.

Authors:  Alassane Dicko; Issaka Sagara; Abdoulaye A Djimdé; Sidy O Touré; Mariam Traore; Souleymane Dama; Abdoulbaki I Diallo; Amadou Barry; Mohamed Dicko; Oumar M Coulibaly; Christophe Rogier; Alexandra de Sousa; Ogobara K Doumbo
Journal:  Malar J       Date:  2010-01-10       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.